BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Pfizer

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) of a 30-µg booster dose of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original [15 µg] and Omicron BA.4/BA.5 [15 µg]) for individuals ages 12 years and older. An application for an Omicron-adapted bivalent vaccine for children 5 through 11 years of age is planned for submission to FDA in

Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older

Moderna

Novavax

They still might offer solid long-term opportunities for investors.

After Double-Digit Percentage Declines, Are Vaccine Stocks Buys?

Moderna's complaint is focused on two critical innovations.

Could This Move by Moderna Cost Pfizer Billions?

Moderna is suing Pfizer and BioNTech over patents it said it filed years ago on the life-saving technology.

Moderna Sues Pfizer Over mRNA Technology Used in COVID Vaccines

Moderna filed a lawsuit against Pfizer and BioNTech claiming the biopharmaceutical companies infringed on Moderna's patents related to mRNA technology in develop of their COVID-19 vaccine. The lawsuit, to be filed in the U.S.

Moderna sues Pfizer, BioNTech over alleged mRNA patent infringement

Moderna Inc. on Friday filed lawsuits against Pfizer Inc. and German partner BioNTech SE, alleging the pair infringed patents relating to its mRNA platform, a key technology behind all of their COVID vaccines.

Moderna sets up clash with Pfizer and BioNTech with patent lawsuits in the U.S. and Germany

Some 16 million Americans of working age have long-term COVID and about 2 to 4 million are not working as they struggle with their symptoms, according to a new report from the Brookings Institution.

Report finds Americans losing up to $1 billion in wages from long COVID, and Moderna sues Pfizer and BioNTech over mRNA patents

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for a booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age and older. This application for a variation of the conditional marketing authorization (cMA) follows guidance from the EMA and International Coalition of Medicines Regulatory Authorities (ICMRA) to work

Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine

Moderna alleges Pfizer and its German partner BioNTech copied their mRNA technology while developing their COVID-19 vaccine.

Moderna sues Pfizer and BioNTech for patent infringement over COVID vaccine

The company says Pfizer and BioNTech copied Moderna's mRNA technology without its permission.

Moderna Sues Pfizer And BioNTech Over Covid-19 Vaccine

Moderna is suing Pfizer and BioNTech for patent infringement, claiming the duo copied its mRNA technology. All three vaccine stocks fell.

Moderna Claims Pfizer, BioNTech Stole Its Patented Tech In Covid Shot

Moderna is suing Pfizer and its German partner BioNTech for alleged patent infringement in the development of the first COVID-19 vaccine approved in the US.

Moderna sues Pfizer/BioNTech over COVID vaccine

In a lawsuit filed in federal court in Massachusetts, Moderna is claiming that its competitors' Covid-19 vaccine infringes on five patents.

Moderna Sues Pfizer, BioNTech for mRNA Patent Infringement

Moderna Inc. MRNA, +0.44% said Friday it is suing Pfizer Inc. PFE, +0.99% and German partner BioNTech SE BNTX, +1.59% for infringing patents relating to its mRNA platform, the source of the COVID vaccines developed by the three parties. The suit is to be filed Friday in the U.S. District Court for the District of Massachusetts and the Regional Court of Düsseldorf in Germany.

Moderna sues Pfizer and BioNTech for patent infringement relating to the mRNA platform used to develop COVID vaccines

Moderna is suing Pfizer and its German partner BioNTech for patent infringement in the development of the first COVID-19 vaccine approved in the United States, alleging they copied technology that Moderna developed years before the pandemic.

Moderna sues Pfizer/BioNTech for patent infringement over COVID vaccine

Americans age 12 and older could begin getting omicron-specific COVID-19 boosters soon after Labor Day, according to a new report.

Omicron-targeting COVID boosters may be out after Labor Day, and Moderna has joined Pfizer and BioNTech in filing for authorization

The three-dose vaccine was most effective in children ages 6 months to 2 years, with a 75.8% efficacy rate, according to the study.

Pfizer-BioNTech Covid Vaccine Is 73% Effective In Young Children, Study Finds

Pfizer and German partner BioNTech on Tuesday offered updated COVID vaccine data supporting efficacy in children aged 6 months through 4 years of age.

Pfizer and BioNTech say data shows COVID vaccine has more than 70% efficacy in small children, and cases now rising in just 7 states

Pfizer Inc. PFE, -0.51% and German partner BioNTech SE BNTX, +0.26% on Tuesday announced updated COVID vaccine data supporting efficacy in children aged 6 months through 4 years of age. The companies said updated analysis from 34 cases occurring at least seven days after a three-dose regimen showed 73.2% vaccine efficacy among children in that age group.

Pfizer and BioNTech say COVID vaccine data showed 73.2% efficacy among children aged 6 month to 4 years

NEW YORK and MAINZ, GERMANY, AUGUST 23, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced updated efficacy results from a Phase 2/3 trial evaluating a three 3-µg dose series of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months through 4 years of age, reinforcing previously reported interim vaccine efficacy data collected in March and April 2022. Emergency Use Authorization (EUA) of this vaccine was granted by the U.S. Food and Drug Administration (FDA) for this age group on June 17 and an application for conditional marketing authorization in this age group is under review by the European Medicines Agency (EMA).

Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age

Pfizer PFE, -0.51% and BioNTech BNTX, +0.26% have formally completed an application asking the Food and Drug Administration to authorize their experimental bivalent COVID-19 booster in those who are 12 years old or older. The new shot equally targets the original strain of the virus and the BA.4 and BA.5 strains, the latter of which is now the dominant strain of SARS-CoV-2 in the U.S. The news comes as U.S. known cases of COVID are continuing to ease, although the true tally is likely higher given how many people are testing at home, where the data are not being collected.

Coronavirus tally: Pfizer and BioNTech formally apply for FDA nod for bivalent COVID booster for people aged 12 and older

Pfizer Inc. PFE, -0.36% and BioNTech SE BNTX, +0.21% said Monday that they formally completed an application asking the Food and Drug Administration to authorize their experimental bivalent COVID-19 booster in those who are 12 years old or older. The new shot equally targets the original strain of the virus and the BA.4 and BA.5 strains.

Pfizer, BioNTech complete FDA submission for new COVID-19 booster

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) of a booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age and older. The application follows guidance from the FDA to include clinical data from the companies' bivalent Omicron BA.1-adapted vaccine and pre-cli

Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine

Pfizer's diversified portfolio of medicines will ensure it keeps outperforming BioNTech.

1 Hot Growth Stock to Buy, and 1 to Avoid (For Now)

Its flagship vaccine product isn't selling as much as it used to.

News for BioNTech SE Stock (BNTX)